PMID- 21875503
OWN - NLM
STAT- MEDLINE
DCOM- 20130503
LR  - 20220321
IS  - 1523-6536 (Electronic)
IS  - 1083-8791 (Print)
IS  - 1083-8791 (Linking)
VI  - 18
IP  - 4
DP  - 2012 Apr
TI  - Immune reconstitution after double umbilical cord blood stem cell 
      transplantation: comparison with unrelated peripheral blood stem cell 
      transplantation.
PG  - 565-74
LID - 10.1016/j.bbmt.2011.08.018 [doi]
AB  - Double umbilical cord blood (DUCB) transplantation is an accepted transplantation 
      strategy for patients without suitable human leukocyte antigen (HLA) matched 
      donors. However, DUCB transplantation is associated with increased morbidity and 
      mortality because of slow recovery of immunity and a high risk of infection. To 
      define the differences in immune reconstitution between DUCB transplantation and 
      HLA matched unrelated donor (MUD) transplantation, we performed a detailed, 
      prospective analysis of immune reconstitution in 42 DUCB recipients and 102 
      filgrastim-mobilized unrelated peripheral blood stem cell recipients. 
      Reconstitution of CD3 T cells was significantly delayed in the DUCB cohort 
      compared with the MUD cohort for 1 to 6 months posttransplantation (P < .001), 
      including naive (CD45RO-) and memory (CD45RO+) CD4 T cells, regulatory (CD4CD25) 
      T cells, and CD8 T cells. In contrast, CD19 B cells recovered more rapidly in the 
      DUCB cohort and numbers remained significantly greater from 3 to 24 months after 
      transplantation (P = .001). CD56CD16 natural killer (NK) cells also recovered 
      more rapidly in DUCB recipients and remained significantly greater from 1 to 24 
      months after transplantation. B cell activating factor (BAFF) levels were higher 
      in the DUCB cohort at 1 month (P < .001), were similar in both cohorts at 3 and 6 
      months, and were lower in the DUCB cohort at 12 months (P = .002). BAFF/CD19 B 
      cell ratios were lower in the DUCB cohort at 3 (P = .045), 6 (P = .02), and 12 
      months (P = .002) after transplantation. DUCB recipients had more infections 
      within the first 100 days after transplantation (P < .001), and there was less 
      chronic graft-versus-host disease (P < .001), but there were no differences in 
      cumulative incidence of relapse, nonrelapse death, progression-free survival, or 
      overall survival between the 2 groups. These results suggest that increased risk 
      of infections is specifically associated with delayed reconstitution of all major 
      T cell subsets, but the increased risk is limited to the first 3 months after 
      DUCB transplantation. There is no increased risk of relapse, suggesting that 
      graft-versus-leukemia activity is maintained. Early reconstitution of B cells and 
      NK cells may, in part, account for these findings.
CI  - Copyright (c) 2012 American Society for Blood and Marrow Transplantation. Published 
      by Elsevier Inc. All rights reserved.
FAU - Jacobson, Caron A
AU  - Jacobson CA
AD  - Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, 
      Massachusetts 02215, USA.
FAU - Turki, Amin T
AU  - Turki AT
FAU - McDonough, Sean M
AU  - McDonough SM
FAU - Stevenson, Kristen E
AU  - Stevenson KE
FAU - Kim, Haesook T
AU  - Kim HT
FAU - Kao, Grace
AU  - Kao G
FAU - Herrera, Maria I
AU  - Herrera MI
FAU - Reynolds, Carol G
AU  - Reynolds CG
FAU - Alyea, Edwin P
AU  - Alyea EP
FAU - Ho, Vincent T
AU  - Ho VT
FAU - Koreth, John
AU  - Koreth J
FAU - Armand, Philippe
AU  - Armand P
FAU - Chen, Yi-Bin
AU  - Chen YB
FAU - Ballen, Karen
AU  - Ballen K
FAU - Soiffer, Robert J
AU  - Soiffer RJ
FAU - Antin, Joseph H
AU  - Antin JH
FAU - Cutler, Corey S
AU  - Cutler CS
FAU - Ritz, Jerome
AU  - Ritz J
LA  - eng
GR  - P01 CA142106-09/CA/NCI NIH HHS/United States
GR  - P01 AI029530-13/AI/NIAID NIH HHS/United States
GR  - T32 CA009172/CA/NCI NIH HHS/United States
GR  - CA142106/CA/NCI NIH HHS/United States
GR  - U19 AI029530/AI/NIAID NIH HHS/United States
GR  - AI29530/AI/NIAID NIH HHS/United States
GR  - P01 CA142106/CA/NCI NIH HHS/United States
GR  - P01 AI029530/AI/NIAID NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20110826
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for 
      Blood and Marrow Transplantation
JID - 9600628
RN  - 0 (Antigens, CD)
RN  - 0 (Biomarkers)
RN  - 0 (HLA Antigens)
SB  - IM
CIN - Biol Blood Marrow Transplant. 2012 Apr;18(4):493-4. PMID: 22338627
MH  - Adult
MH  - Aged
MH  - Antigens, CD/immunology
MH  - B-Lymphocytes/cytology/immunology
MH  - Biomarkers/analysis
MH  - CD4-Positive T-Lymphocytes/cytology/immunology
MH  - CD8-Positive T-Lymphocytes/cytology/immunology
MH  - Cord Blood Stem Cell Transplantation/*methods
MH  - Female
MH  - Graft vs Host Disease/immunology
MH  - HLA Antigens/immunology
MH  - Humans
MH  - *Immunity, Innate
MH  - Killer Cells, Natural/cytology/immunology
MH  - Male
MH  - Middle Aged
MH  - Peripheral Blood Stem Cell Transplantation
MH  - Prospective Studies
MH  - Recurrence
MH  - Risk
MH  - Survival Analysis
MH  - Transplantation, Homologous
MH  - Unrelated Donors
PMC - PMC3288552
MID - NIHMS333251
EDAT- 2011/08/31 06:00
MHDA- 2013/05/04 06:00
PMCR- 2013/04/01
CRDT- 2011/08/31 06:00
PHST- 2011/07/29 00:00 [received]
PHST- 2011/08/19 00:00 [accepted]
PHST- 2011/08/31 06:00 [entrez]
PHST- 2011/08/31 06:00 [pubmed]
PHST- 2013/05/04 06:00 [medline]
PHST- 2013/04/01 00:00 [pmc-release]
AID - S1083-8791(11)00351-X [pii]
AID - 10.1016/j.bbmt.2011.08.018 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 2012 Apr;18(4):565-74. doi: 
      10.1016/j.bbmt.2011.08.018. Epub 2011 Aug 26.